ELICIO THERAPEUTICS I

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

31 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

16 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

17 Sep 2024 08:31:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

13 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

13 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

28 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Proposed Public Offering

27 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

27 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

18 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

23 May 2024 17:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 May 2024 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

25 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

05 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

29 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

18 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

05 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

25 Jan 2024 09:00:00 By Nasdaq GlobeNewswire